83 related articles for article (PubMed ID: 15570541)
1. [Alterations of gait parameters under external cueing in schizophrenic patients: a switch study].
Putzhammer A; Perfahl M; Pfeiff L; Broll K; Hess L; Ibach B
Psychiatr Prax; 2004 Nov; 31 Suppl 1():S164-6. PubMed ID: 15570541
[TBL] [Abstract][Full Text] [Related]
2. [3-D ultrasound-assisted gait analysis of schizophrenic patients. Comparison between conventional neuroleptics and olanzapine].
Putzhammer A; Heindl B; Müller J; Broll K; Pfeiff L; Perfahl M; Hess L; Koch H
Psychiatr Prax; 2003 May; 30 Suppl 2():S110-4. PubMed ID: 14509054
[TBL] [Abstract][Full Text] [Related]
3. [Three-Dimensional Ultrasonic Gait Analysis in Schizophrenic Patients].
Putzhammer A; Heindl B; Müller J; Broll K; Pfeiff L; Perfahl M; Hess L; Koch H
Psychiatr Prax; 2003 May; 30(Suppl 2):110-114. PubMed ID: 13130352
[TBL] [Abstract][Full Text] [Related]
4. Gait disturbances in patients with schizophrenia and adaptation to treadmill walking.
Putzhammer A; Perfahl M; Pfeiff L; Hajak G
Psychiatry Clin Neurosci; 2005 Jun; 59(3):303-10. PubMed ID: 15896224
[TBL] [Abstract][Full Text] [Related]
5. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.
Schlagenhauf F; Juckel G; Koslowski M; Kahnt T; Knutson B; Dembler T; Kienast T; Gallinat J; Wrase J; Heinz A
Psychopharmacology (Berl); 2008 Mar; 196(4):673-84. PubMed ID: 18097655
[TBL] [Abstract][Full Text] [Related]
6. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
[TBL] [Abstract][Full Text] [Related]
7. The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study.
Jakovljevic M; Pivac N; Mihaljevic-Peles A; Mustapic M; Relja M; Ljubicic D; Marcinko D; Muck-Seler D
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):399-402. PubMed ID: 17126974
[TBL] [Abstract][Full Text] [Related]
8. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
9. Spatial and temporal parameters of gait disturbances in schizophrenic patients.
Putzhammer A; Heindl B; Broll K; Pfeiff L; Perfahl M; Hajak G
Schizophr Res; 2004 Aug; 69(2-3):159-66. PubMed ID: 15469189
[TBL] [Abstract][Full Text] [Related]
10. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
Kong DS; Yeo SH
Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
[TBL] [Abstract][Full Text] [Related]
11. Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol.
Ehmann TS; Delva NJ; Beninger RJ
J Clin Psychopharmacol; 1987 Jun; 7(3):173-5. PubMed ID: 3298328
[TBL] [Abstract][Full Text] [Related]
12. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
13. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
Allan ER; Sison CE; Alpert M; Connolly B; Crichton J
Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201
[TBL] [Abstract][Full Text] [Related]
14. Atypical (olanzapine) plus conventional (fluphenazine) neuroleptic treatment associated with the neuroleptic malignant syndrome.
Tofler IT; Ahmed B
J Clin Psychopharmacol; 2003 Dec; 23(6):672-4. PubMed ID: 14624203
[No Abstract] [Full Text] [Related]
15. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
16. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine vs haloperidol for treatment of schizophrenia.
Glazer WM
JAMA; 2004 Mar; 291(9):1064-5; author reply 1065-6. PubMed ID: 14996766
[No Abstract] [Full Text] [Related]
18. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
19. Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients. Results from an experimental study.
Kagerer S; Winter C; Möller HJ; Soyka M
Neuropsychobiology; 2003; 47(4):212-8. PubMed ID: 12824745
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial.
Gattaz WF; Diehl A; Geuppert MS; Hubrich P; Schmitt A; Linde I; Maras A; Dittmann RW
Pharmacopsychiatry; 2004 Nov; 37(6):279-85. PubMed ID: 15551194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
